Figure 2.

Increased proportions of CD4+CD25-Foxp3+ T cells in patients treated with cyclophosphamide. Patients were subdivided into groups according to their immunosuppressive treatment. MMF, mycofenolate mofetil; MTX, methotrexate; AZA, azathioprine; CYC, cycophosphamide. Significantly higher proportions of CD4+CD25-Foxp3+ T cells were observed in systemic lupus erythematosus (SLE) patients who were treated with cyclophosphamide as compared to patients with other treatment regimes (P = 0.0001). *Significant differences.

Bonelli et al. Arthritis Research & Therapy 2014 16:R104   doi:10.1186/ar4553
Download authors' original image